Dernières nouvelles pour Regenxbio (NASDAQ:RGNX) Stock

REGENXBIO INC

Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Inc

News

Osisko Development To Raise Up To $195M Through Brokered And Non-Brokered Offerings At $2.05 Per Unit

Baird analyst Michael Ha downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Neutral to Underperform and lowers the price target from $312 to $198.

Downgrades

Price Target

Analyst Ratings

Baird Downgrades UnitedHealth Group to Underperform, Lowers Price Target to $198

Rosenblatt analyst Kevin Cassidy maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and maintains $180 price target.

Rosenblatt Maintains Buy on ARM Holdings, Maintains $180 Price Target

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">
BAXTER INTERNATIONAL INC.
Reconciliation of Non-GAAP Financial Measures
Projected Third Quarter and Full Year 2025 U.S. GAAP Sales Growth to Projected Operational Sales Growth and Projected Third Quarter and Full Year 2025 Adjusted Earnings Per Share
(unaudited)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales Growth Guidance</td>
<td colspan="1" rowspan="1">Q3 2025&#x2A;</td>
<td colspan="1" rowspan="1">FY 2025&#x2A;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales growth - U.S. GAAP</td>
<td colspan="1" rowspan="1">6% - 7%</td>
<td colspan="1" rowspan="1">6% - 7%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Kidney Care MSA</td>
<td colspan="1" rowspan="1">(~300 bps)</td>
<td colspan="1" rowspan="1">(~300 bps)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Exit of IV Solutions in China</td>
<td colspan="1" rowspan="1">~70 bps</td>
<td colspan="1" rowspan="1">~50 bps</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Foreign Exchange</td>
<td colspan="1" rowspan="1">(~100 bps)</td>
<td colspan="1" rowspan="1">(~50 bps)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operational sales growth</td>
<td colspan="1" rowspan="1">3% - 4%</td>
<td colspan="1" rowspan="1">3% - 4%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Adjusted Earnings Per Share Guidance</td>
<td colspan="1" rowspan="1">Q3 2025</td>
<td colspan="1" rowspan="1">FY 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted EPS</td>
<td colspan="1" rowspan="1">$0.58 - $0.62</td>
<td colspan="1" rowspan="1">$2.42 - $2.52</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&#x2A;Totals may not foot due to rounding</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Baxter Intl Sees Q3 Adj EPS $0.58-$0.62 vs $0.65 Est

QuantaSing To Fully Acquire Letsvan Via Share Deal, Issuing 18.2M Class A Shares; Appoints Founder Zack Zhan To Board Effective August 1

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and raises the price target from $50 to $65.

IONS

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $65

Baxter Intl Lowers FY2025 Adj EPS Guidance from $2.47-$2.55 to $2.42-$2.52 vs $2.52 Est; Lowers FY2025 Sales Guidance from $11.381B-$11.487B to $11.274B-$11.380B vs $11.378B Est

Electra Battery Materials Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>, TSXV:<a href="https://www.benzinga.com/stock/ELBM#TSXV">ELBM</a>) ("Electra" or the "Company") announces the start of metallurgical testing on cobalt feedstock from two strategic North American sources: the historic Cobalt Camp in Ontario and home to Electra's refinery, and the Company's Iron Creek cobalt and copper project in Idaho.
The objective of this initiative is to strengthen and diversify Electra's cobalt refinery feedstock pipeline by integrating domestic sources alongside existing global supply partners. This program supports the development of a robust, flexible, and resilient North American critical minerals supply chain while maintaining strategic relationships with partners such as Glencore and ERG. These domestic sources are intended to supplement Electra's existing international feedstock agreements, enhancing long-term security and operational flexibility.
Preliminary results from Electra's North American feedstock program are expected by the end of 2025 and will inform potential front-end flowsheet modifications, such as the proposed addition of a pressure oxidation (POX) circuit to enable processing of a broader range of complex concentrates. Electra's in-house laboratory is in the process of installing equipment required to evaluate these new feedstocks. Backed by a highly experienced technical team, the lab will conduct bench-scale testing and analytical work to validate and refine proposed flowsheet enhancements to the leach circuit designed to process North American materials at the Company's hydrometallurgical refinery, including arsenic-bearing polymetallic sulfide materials.

ELBM

Electra Begins Testing US and Canadian Cobalt to Boost North American Battery Supply Chain

XRTX

XORTX Announces $114,500 Private Placement To Support Gout Programs; Units Priced At $0.73 With 60-Month Warrants Exercisable At $1.20

<ul>
<li>Visa cardholders will score exclusive first access for a chance to purchase tickets to the world's biggest tournament</li>
<li>Visa plans to help local businesses in Canada, Mexico and the United States get ready to maximize economic opportunity</li>
</ul>

Visa And FIFA Team Up To Offer Global Cardholders Priority Access To World Cup 26 Tickets With Exclusive Presale

Baird analyst Peter Arment downgrades Albany International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) from Outperform to Neutral and maintains the price target from $79 to $79.

Baird Downgrades Albany International to Neutral, Maintains Price Target to $79

MRNA

Moderna To Cut Workforce By ~10%

Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) affirms FY2025 sales outlook from $11.800 billion-$12.200 billion to $11.800 billion-$12.200 billion vs $11.908 billion estimate.

Huntington Ingalls Indus Affirms FY2025 Sales Guidance of $11.800B-$12.200B vs $11.908B Est

Second Quarter 2025&nbsp;HIGHLIGHTS
Corporate&nbsp;Highlights
<ul>
<li>Safety:&nbsp;The Nevada Mining Association&nbsp;("NVMA") awarded Hycroft the 2025 first place NVMA Operator Safety&nbsp;Award for small surface mines.&nbsp;Hycroft has maintained a 0.00 TRIFR for more than two and a half years, operating over 1.3-million-man hours without a Lost Time Incident. &nbsp;</li>
<li>Environmental:&nbsp; Through June 30, 2025, Hycroft maintained an impeccable environmental record and was recognized as stewards of successful reclamation. &nbsp;</li>
<li>Balance&nbsp;Sheet:&nbsp;The&nbsp;Company&nbsp;ended&nbsp;the&nbsp;second quarter&nbsp;with&nbsp;unrestricted cash of $68.8&nbsp;million, restricted cash of $30.0 million&nbsp;and total debt of $131.0 million.</li>
</ul>

Earnings

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

Hycroft Mining Holding Ended Q2 With $98.8M Cash

Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) affirms FY2025 Adj EPS guidance from $0.75-$0.88 to $0.75-$0.88 vs $0.78 analyst estimate. Affirms FY2025 sales outlook from $3.069 billion to $3.069 billion vs $2.921 billion estimate.

STGW

Stagwell Affirms FY2025 Adj EPS Guidance of $0.75-$0.88 vs $0.78 Est; Affirms FY2025 Sales Guidance of $3.069B vs $2.921B Est

Biotech

Health Care

Management

General

BCRX

BioCryst Pharmaceuticals' President And CEO, Jon Stonehouse Will Retire On December 31, The Company Has Appointed Charlie Gayer, Currently The Company's Chief Commercial Officer, As The Next President, Effective August 1, And Next CEO, Effective January 1, 2026

Rosenblatt analyst Kevin Cassidy maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $53 to $90.

Rosenblatt Maintains Buy on Western Digital, Raises Price Target to $90

Idaho Strategic Acquires Toboggan Project From Hecla Mining, Unifying Murray Gold Belt For First Time; Adds 143.5 Acres Of Patented Claims And Multiple Untested Gold Prospects

Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported quarterly earnings of $0.59 per share which missed the analyst consensus estimate of $0.61 by 3.28 percent. This is a 28.26 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $2.810 billion which missed the analyst consensus estimate of $2.823 billion by 0.45 percent. This is a 4.31 percent increase over sales of $2.694 billion the same period last year.

Earnings Misses

Baxter Intl Q2 Adj. EPS Cont. Ops. $0.59 Misses $0.61 Estimate, Sales $2.810B Miss $2.823B Estimate

<ul>
<li>Mobilicom's BlueUAS listed SkyHopper PRO software-defined radios and advanced OS3 cybersecurity software are fully integrated with ARK's made-in-USA, BlueUAS listed Jetson PAB Carrier, powered by NVIDIA</li>
<li>Made-in-the-USA, NDAA compliant product to be sold to defense and commercial markets</li>
<li>Serves the small sized drones market projected to reach <a href="https://www.globenewswire.com/Tracker?data=MlOatB4DmlBeS_bZktSaM4EXqLixwYpdOROsPSASr7mUPWX3eTi0XWt11Sk4Ym35Rt2jXUmLTxaJCo296NdTmxFUiPSLb-vp_yD1w3pSIyejjTrzfDRwz53xXbbX6j8OVoWVnl_r7R0qAxGcRk5MYMUpLDyeZJjrfuSY2trzKjs=">$11 billion</a> by 2030</li>
</ul>

Mobilicom And ARK Debut Turnkey Drone Platform Integrating SkyHopper PRO And NVIDIA-Powered Jetson PAB Carrier

Press Releases

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Comments

Regenxbio

Actualités

Dernières nouvelles pour Regenxbio (NASDAQ:RGNX) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL